STAT3 and prostate cancer: In line with these results, 6‐shogaol diminished the constitutive phosphorylation of STAT3 in human prostate cancer cell lines (DU145 and HMVP2) and decreased the IL‐6‐induced activation of STAT3 in LNCaP (Saha et al., 2014).